



# Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



Original article

## Screening for strongyloidiasis in Spain in the context of the SARS-CoV-2 pandemic: Results of a survey on diagnosis and treatment



Azucena Rodríguez-Guardado<sup>a,\*,1</sup>, Miriam J. Álvarez-Martínez<sup>b,1</sup>, María Delmans Flores<sup>c,1</sup>, Elena Sulleiro<sup>d,1</sup>, Diego Torrús-Tendero<sup>e,1</sup>, María Velasco<sup>f,1</sup>, Francisco Javier Membrillo<sup>g,1</sup>, on behalf of the Imported Pathology Group of the SEIMC

<sup>a</sup> Área de Gestión Clínica Medicina Interna, Hospital Universitario Central de Asturias, Grupo de Microbiología Traslacional, Instituto de Investigación del Principado de Asturias, Asturias, Spain

<sup>b</sup> Departamento de Microbiología, Hospital Clínic, Instituto de Salud Global Barcelona, Hospital Clínic, Universidad de Barcelona, Barcelona, Spain

<sup>c</sup> Unidad de Leishmania y Chagas, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain

<sup>d</sup> Servei Microbiologia, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

<sup>e</sup> Unidad de Referencia de Enfermedades Importadas y Salud Internacional, Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Área de Parasitología, Universidad Miguel Hernández, Alicante, Spain

<sup>f</sup> Sección Infecciosas, Medicina Interna, Unidad de Investigación Hospital Universitario Fundación Alcorcón, Profesorado Asociado a Medicina, Universidad Rey Juan Carlos, Madrid, Spain

<sup>g</sup> Unidad NRBQ-Infecciosas, Sección de Infecciosas, UAA, Hospital Central de la Defensa «Gómez Ulla», Madrid, Spain

### ARTICLE INFO

#### Article history:

Received 10 August 2021

Accepted 6 November 2021

Available online 12 August 2022

#### Keywords:

Strongyloides stercoralis

Strongyloidiasis

COVID-19

SARS-CoV-2

Screening

### ABSTRACT

**Introduction:** The generalization of treatment with dexamethasone or other immunosuppressants in patients with SARS-CoV-2 infection may increase the risk of occurrence of severe forms of strongyloidiasis. A nationwide survey was conducted to better understand the diagnostic and therapeutic situation of strongyloidiasis in SARS-CoV-2 co-infected patients in Spain.

**Materials and methods:** A survey was designed and sent to all SEIMC members during February and March 2021. Responses were exported for computer processing to Microsoft Excel 2017 and statistically processed with the free software PSPP.

**Results:** 189 responses were received, of which 121 (64%) were selected for further processing. Eighty-four centers (69.5%) had no specific strongyloidiasis screening protocol. Forty-two centers (34.7%) had serological techniques available in their laboratories and the rest were sent to a reference laboratory. Only 22 centers (18%) screened for strongyloidiasis in SARS-CoV-2 infected patients. A total of 227 cases of strongyloidiasis were diagnosed in patients with SARS-CoV-2 infection. In four cases patients developed a massive hyperinfestation syndrome leading to the death of one patient.

**Conclusion:** COVID-19 has highlighted the need to unify screening and treatment protocols for imported pathologies such as strongyloidiasis. Efforts to disseminate knowledge are needed to ensure that this potentially fatal disease is adequately treated in patients with the highest risk of complications, such as those with COVID-19.

© 2022 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.

DOI of original article: <https://doi.org/10.1016/j.eimc.2021.11.010>

\* Corresponding author.

E-mail address: [azucenarodriguez@telecable.es](mailto:azucenarodriguez@telecable.es) (A. Rodríguez-Guardado).

<sup>1</sup> All the authors contributed equally to this article.

## Cribado de estrongiloidiosis en España en el contexto de la pandemia SARS-CoV-2: resultados de una encuesta sobre diagnóstico y tratamiento

### R E S U M E N

**Palabras clave:**  
*Strongyloides stercoralis*  
 Estrongiloidiosis  
 COVID-19  
 SARS-CoV-2  
 Cribado

**Introducción:** La generalización del tratamiento con dexametasona u otros inmunosupresores en pacientes con infección SARS-CoV-2 puede aumentar el riesgo de aparición de formas graves de estrongiloidiosis. Se realizó una encuesta a nivel nacional para conocer mejor de la situación diagnóstica y terapéutica de la estrongiloidiosis en España en pacientes coinfectados por SARS-CoV-2.

**Materiales y métodos:** Se diseñó una encuesta que fue enviada a todos los miembros de SEIMC durante los meses de febrero y marzo de 2021. Las respuestas se exportaron para su procesamiento informático al programa Microsoft Excel 2017 y se procesaron estadísticamente con el software libre PSPP.

**Resultados:** Se recibieron 189 respuestas de las cuales se seleccionaron 121 (64%) para su procesamiento posterior. En ochenta y cuatro centros (69.5%) no existía ningún protocolo de cribado específico de estrongiloidiosis. Cuarenta y dos centros (34.7%) disponían de técnicas serológicas en sus laboratorios y en el resto se enviaban a un laboratorio de referencia. Solo 22 centros (18%) realizaron cribado de estrongiloidiosis en pacientes infectados por SARS-CoV-2. Se diagnosticaron 227 casos de estrongiloidiosis en pacientes con infección por el SARS-CoV-2. En cuatro casos los pacientes desarrollaron un síndrome de hiperinfestación masiva que condujo al fallecimiento de uno.

**Conclusión:** La COVID-19 ha puesto de manifiesto la necesidad de unificar protocolos de cribado y tratamiento de patologías importadas como la estrongiloidiosis. Es necesario realizar un esfuerzo de difusión del conocimiento para que esta patología potencialmente mortal sea tratada adecuadamente en los pacientes con mayor riesgo de complicaciones como son aquellos con COVID-19.

© 2022 Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.

### Introduction

Strongyloidiasis is an infection caused by *Strongyloides stercoralis*, a globally prevalent nematode. It is estimated that at least 370 million people are infected worldwide, with a high degree of endemic burden found in tropical areas of Southeast Asia, sub-Saharan Africa and Latin America<sup>1</sup>. Its distinctive characteristics include its ability to persist and replicate in the host through an auto-infection cycle that allows it to survive over the years and its capacity to produce severe clinical symptoms, mainly in immunosuppressed patients, such as hyperinfection syndrome or disseminated strongyloidiasis associated with high mortality rates<sup>2,3</sup>. The factors favouring these disseminated forms include the use of steroids or other immunosuppressive treatments, the presence of solid or haematological neoplasms, human immunodeficiency virus (HIV) infection or being a transplant recipient<sup>4–7</sup>. Moreover, the disseminated forms can produce symptoms similar to those of septic shock or another infection with severity criteria such as meningitis, making it difficult to distinguish in the absence of adequate diagnostic suspicion. In the case of patients with COVID-19, the emergence of new pulmonary infiltrates accompanied by clinical and blood gas deterioration may be indistinguishable from the evolution of the SARS-CoV-2 infection, complicating prognosis even further.

The outbreak of the SARS-CoV-2 pandemic posed an unprecedented challenge from the standpoint of infectious diseases, not only because of the appearance of the actual virus but also because of its influence on the reactivation of other concomitant infections. In the case of parasites, this influence is poorly characterised<sup>8</sup>, but the generalisation of treatment with dexamethasone or other immunosuppressants<sup>9,10</sup> in patients with SARS-CoV-2 infection is expected to increase the risk of the appearance of severe forms of strongyloidiasis in the absence of adequate and early diagnostic suspicion<sup>11–13</sup>. In addition, the combination of dexamethasone with tocilizumab, an IL-6 inhibitor known to improve survival in patients with COVID-19 with hyperinflammation<sup>10</sup>, could be an additional risk factor for disseminated strongyloidiasis<sup>14</sup> due to an decreased Th2 immune response conducive to nematode infections<sup>15,16</sup>.

We decided to conduct a nationwide survey in order to glean a better understanding of the diagnostic and therapeutic situation of strongyloidiasis in Spain and more specifically in patients co-infected with SARS-CoV-2.

### Materials and methods

For the purposes of the study, a survey was designed based on the opinion of a panel of experts from the Grupo de Patología Importada [Imported Pathology Group] (GEPI) of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica [Spanish Society of Infectious Diseases and Clinical Microbiology] (SEIMC). The SEIMC is the main Spanish society for infectious diseases and has 4001 members, 1946 of whom practice clinical microbiology, whereas 2055 are infectious disease specialists. The society's excellent implantation in Spain made it possible to obtain the high level of participation shown in the results, covering practically all the Autonomous Communities and a wide array of centres, which was fundamental in guaranteeing a representative sample.

The questions posed included: a) general characteristics of the centre (number of hospital beds, existence of an imported diseases specialised unit, a specific unit for parasitology in the microbiology laboratory, activity of the microbiology laboratory 24/7; b) staffing and equipment of the microbiology laboratory, including the techniques and protocols used for screening and diagnosis of strongyloidiasis; c) access to screening for strongyloidiasis in patients with SARS-CoV-2; d) availability of treatment for strongyloidiasis.

The survey was designed using the Google Forms platform and was sent to all SEIMC members in February and March 2021. If responses were received from several members of the same hospital, a single response was selected. The responses were exported to Microsoft Excel 2017 for computer processing and were statistically processed with the free PSPP software.

### Results

Initially, 189 responses were received, 121 (64%) of which were selected for subsequent processing after duplicate centres had been



**Fig. 1.** Number of participating hospitals by Autonomous Community.

removed. The responses covered all the autonomous communities in Spain (Fig. 1).

*General characteristics*

Regarding the number of hospital beds, most of the completed surveys corresponded to centres with 100–499 beds (50.4%), followed by hospitals with 500–999 (29%), those with more than 1000 beds (13.2%) and those with less than 100 beds (7.4%). With regard to the type of microbiology laboratory service, 66 served both the hospital and the health centres under the authority of their area, 44 were reference laboratories and the rest provided only hospital care. The general characteristics of the centre are shown in Table 1.

*Clinical and microbiological diagnosis*

In 84 of the 121 centres (69.5%) there was no specific screening protocol for strongyloidiasis. Of the remaining centres, in 21 (17.3%) screening was performed in all patients from endemic areas and in the other 16 (13.2%) screening was only performed in the presence of risk factors that included HIV infection in all of them, transplant in 13, although only 4 were screened in the case of steroid treatment (Table 2).

In the microbiology laboratory, the diagnosis of strongyloidiasis was made predominantly only at the request of the attending physician (71 centres, 59%). In 19 (16%) centres, in addition to the physician's request, diagnosis was added in the case of eosinophilia. In 11 (9%) centres it was performed according to both the laboratory's own protocols and at the request of the attending physician. Five centres (4%) did so only in the case of eosinophilia, and another 5 only in the case of compatible symptoms.

**Table 1**  
General characteristics of the participating centres.

Parameters	n = 121
<i>Hospital type</i>	
<100 beds	9 (7.4%)
between 100 and 499	61 (50.4%)
between 500 and 999	35 (29%)
>1000 beds	16 (13.2%)
<i>Continuous microbiology care</i>	
No	34 (28%)
Yes	87 (72%)
Physically present	49 (56%)
Part-time physically present	24 (28%)
Local	14 (16%)
<i>Microbiologist dedicated to parasitology</i>	
No	25 (20.7%)
Yes	96 (79.3%)
Full-time	25
Part-time	71
<i>Centre has an imported disease unit</i>	
Yes	33 (27.3%)
No	88 (72.7%)
<i>Type of microbiology laboratory</i>	
Linked to a single hospital centre	56 (46.3%)
Laboratory for several hospital centres	63 (52%)
Other	2 (1.7%)
<i>Type of activity of the microbiology laboratory</i>	
Reference for other local centres	41 (34%)
Non-reference hospital care and primary care	66 (54.5%)
Hospital only	14 (11.5%)

Forty-two (42) centres (34.7%) had serological techniques available in their laboratories, whereas they were sent to a reference laboratory in the other cases.

**Table 2**  
Situation regarding the clinical and microbiological diagnosis.

Parameters	n = 121
<b>Availability of Strongyloides serology</b>	
No (send to reference centre)	79 (65.3%)
Yes	42 (34.7%)
<b>Microbiological diagnosis</b>	
Only at the request of the attending physician	71 (58.7%)
Within the centre's screening protocols	10 (8.1%)
Both	11 (9%)
At the request of the attending physician and/or if eosinophilia	19 (16%)
Only in case of eosinophilia	5 (4%)
Only if clinical suspicion	5 (4%)
<b>Specific screening protocol</b>	
No	84 (69.4%)
All patients from endemic areas	21 (17.3%)
From endemic areas only in the event of risk factors	16 (13.2%)
Transplants	13
HIV infection	16
Steroids	4
<b>Screening in patients with COVID-19</b>	
Yes	22 (18.2%)
No	99 (81.8%)
<b>In which patients with COVID-19 screening was performed</b>	
In those from endemic areas	23
Only in those from Latin America	7
Only in the immunosuppressed	4
<b>Method chosen</b>	
Serology	16
Serology + culture	4
Culture only	2
<b>Cases of Strongyloides and SARS-CoV-2 co-infection</b>	
Yes	23
No	98
<b>Number of cases</b>	
Massive hyperinfestation syndrome	4
Secondary deaths	1
Secondary bacteraemia sepsis	1
<b>Diagnostic strategy</b>	
No screening	92
Empiric treatment without diagnostic test	7
Screening carried out prior to treatment	22
<b>Treatment</b>	
Ivermectin	39
Albendazole	2
Both	1
<b>Stock of ivermectin</b>	
No	45
Yes	31
Not known	37

HIV: human immunodeficiency virus.

### SARS-CoV-2 and strongyloidiasis coinfection

Only 22 centres (18%) screened for strongyloidiasis in patients infected with SARS-CoV-2. Among the techniques used for screening, 90.9% of the centres used serology as the only diagnostic test. In two centres, the serology was complemented with culture in blood agar and culture was performed exclusively in two centres. Seven centres chose to start empiric treatment with ivermectin in the case of high clinical suspicion without performing a prior microbiological diagnosis.

A total of 227 cases of strongyloidiasis were diagnosed in patients with SARS-CoV-2 infection, corresponding to 23 centres. In 4 cases, the patients developed a massive hyperinfestation syndrome that led to the death of one of them. One case developed bacterial-origin sepsis. The most utilised treatment was ivermectin, although albendazole was used in 2 cases and both of them in 1 patient. Ivermectin was available in the hospital only in 31 centres

(25.6%), in 37 centres it proved impossible to ascertain the situation and in the rest it was not available.

### Discussion

The generalisation of steroid and immunomodulatory treatment for SARS-CoV-2 infection has heightened concerns about the emergence of severe forms of strongyloidiasis in at-risk patients. Our survey revealed a high number, and possibly underdiagnosed, of patients with *S. stercoralis* and SARS-CoV-2 co-infection, which is not surprising given the high prevalence of infection in the immigrant population. Previous studies report global seroprevalence rates of *S. stercoralis* of 12.2% in this group, reaching 17.3% in the case of immigrants from Asia, 14.6% for immigrants from sub-Saharan Africa and 11.4% for those from the Caribbean and Latin America<sup>11</sup>. Studies conducted in Spain on 12,796 patients found similar prevalences (9.7%), although in this case the main area of provenance was South America<sup>17–19</sup>.

As was to be expected, given the high number of immigrants residing in Spain, they have frequently been infected by SARS-CoV-2, with some studies observing a higher risk of infection in both Latin American and sub-Saharan patients<sup>20</sup>.

Previous works<sup>21</sup> conducted in Spain show that up to 11% of patients hospitalised for COVID-19 had been born outside the country, were mostly of Latin American origin (5.9%) and they accounted for 3.3% of deaths.

In this context of high prevalence and nonspecific, or even absent, symptoms, most experts and international organisations concur on the need to screen and treat the population from high prevalence areas<sup>22,23</sup>. The Canadian clinical guidelines for immigrants and refugees consider screening for strongyloidiasis in immigrants from endemic areas with (i) signs and/or symptoms consistent with infection and/or (ii) eosinophilia<sup>22</sup>. The presence of eosinophilia is a sign that is classically associated with strongyloidiasis. However, there is little correlation between positive serology and the presence of eosinophilia in the blood. Although it is true that serology is more frequently positive in patients with eosinophilia, serology can also be positive in its absence, perhaps because it generally occurs in response to tissue invasion by a parasite, which is why it occurs intermittently and may be missed if just a single complete blood count is examined. Even lower rates of eosinophilia have been found in immunocompromised patients, and the sensitivity, specificity, and positive predictive value in cases of massive hyperinfestation syndrome are considered to be even lower<sup>3,19</sup>. For these reasons, other organisations consider that screening should be based fundamentally on the patients' area of origin<sup>23</sup>. In this regard, the *European Centre for Disease Control* recommends that serology screening be carried out in all immigrants with a high risk of exposure to *S. stercoralis*, regardless of the eosinophilia value (evidence level III D), with immigrants from Central and South America, sub-Saharan Africa and Southeast Asia being understood to be high-risk<sup>23</sup>. In the specific case of patients co-infected with SARS-CoV-2, there is a significant change in immunity, and the most severe cases are also associated with eosinopenia, which can mask the suspicion of this parasitic disease if only this marker is taken into account<sup>24</sup>.

Despite these institutional recommendations, our results show that there was only a specific screening protocol for strongyloidiasis in just over one third of the cases at the centre and that in those where it existed it only covered the immunocompromised population, in many cases without steroid treatment being included in this group, despite it being the main risk factor. This lack of clinical protocols correlates with the lack of protocols in microbiology laboratories, and in most cases the diagnosis is based solely on the opinion of the attending clinician and is completed with other cri-

teria such as the presence of eosinophilia. As we already pointed out, the chronic forms of strongyloidiasis frequently course with non-specific symptoms and even without symptoms, hence the existence of both clinical and microbiological protocols is essential to reach an early diagnosis.

The choice of techniques used in screening varies depending on their availability and the experience of each laboratory. The definitive diagnosis of strongyloidiasis is made by detecting larvae in faeces. However, due to the intermittent shedding of larvae, the sensitivity of the microscopic examination of a single sample is low and is negative in up to 70% of cases. Different techniques have been used to improve the sensitivity of microscopic techniques, such as the Baermann technique, the formalin-ethyl acetate concentration technique, the Harada-Mori method with culture on filter paper moistened with hot water and cultures on blood agar plates<sup>25</sup>. Studies using stool microscopy have reported lower prevalence rates (0.8%–4.3%) than those obtained using serologic enzyme immunoassays (9%–77%)<sup>25,26</sup>, so serology is currently considered the method of choice for screening. Our study reveals that despite this, only 42 (34.7%) of the centres surveyed had serological techniques available at their laboratories and in the rest of the cases they were sent to a reference laboratory, substantially delaying the arrival of results.

Perhaps for this reason our results show that screening in patients with COVID-19 was scant and was only carried out in 18% of the centres surveyed. Despite this scant coverage, 227 cases of *Strongyloides* infection were diagnosed, giving some idea of the magnitude the infection could reach if screening were mainstreamed to cover the rest of the centres.

Since the responses to this study were voluntary, the real figure regarding the availability of serological techniques and centres with a screening protocol in all Spanish hospitals could be even lower due to the possibility of obtaining a lower response rate to the survey in centres that are not aware of the problem and therefore do not carry out screening.

In the case of patients with COVID-19, this screening is especially important due to the ability of *S. stercoralis* to persist and replicate in a host for long periods of time, as well as its potential to spread and cause life-threatening infection in an immunocompromised host. In the presence of some predisposing conditions such as immunosuppression due to the use of steroids or other drugs, transplant recipients or haematological patients, the disease can lead to severe forms such as hyperinfection syndrome or disseminated strongyloidiasis with variable prevalence and associated high rates of mortality<sup>3,4,11,19</sup>. The use of steroids has been shown to be the main predisposing factor for severe forms of strongyloidiasis regardless of the dose of the steroid<sup>2,19</sup>. In the study by Salvador et al.<sup>4</sup>, 83% of the patients had received a mean of 40 mg of prednisone, but the appearance of disseminated strongyloidiasis with doses of 20 mg of prednisone has been described. It also seems to be independent of treatment time and appears both in the case of single doses and in prolonged regimens<sup>19</sup>. The facilitating role played by other immunomodulators such as tocilizumab has been less studied, although it could be associated with reactivations of both this and other parasites<sup>15,16,27</sup>. Isolated cases of reactivation of strongyloidiasis have been described in patients on treatment with etanercept<sup>16</sup>.

The publication of the RECOVERY<sup>9</sup> study data, demonstrating the benefit of steroid treatment in patients hospitalised for COVID-19 who required supplemental oxygen, has led to the generalised and worldwide use of dexamethasone. After the generalisation of steroid treatment for COVID-19, many of these patients from areas of high prevalence of *S. stercoralis* have received dexamethasone alone or in combination with tocilizumab. Rodríguez-Baño et al.<sup>28</sup> describe the results of a cohort of patients treated with steroids at conventional and bolus doses, and/or tocilizumab. It is striking that

8% of the patients treated with tocilizumab were non-Caucasian, as were 2.7% of those treated with moderate-dose corticosteroids and 3.8% of those who received pulse steroids. This percentage rose to 10.2% in those who received combined treatment.

In this scenario, in which the generalisation of steroid treatment in the SARS-CoV-2 pandemic and the high prevalence of *S. stercoralis* in the immigrant population is combined, the possibility of a reactivation of strongyloidiasis becomes a significant and possibly underdiagnosed problem, since the symptoms of the disseminated form (appearance of pulmonary infiltrates, adult respiratory distress syndrome, digestive symptoms, etc.) can be indistinguishable from those presented by patients with COVID-19. Occasional cases of disseminated infection that required specific treatment with good evolution have been described in the literature<sup>12,13,29,30</sup>. All the cases had previously received steroids and one of them tocilizumab as well.

A specific strategy<sup>31</sup> based on epidemiological risk stratification<sup>22</sup> has recently been proposed to prevent *Strongyloides* hyperinfection/disseminated infection in patients with COVID-19 on treatment with steroids. This strategy proposes empiric treatment with ivermectin for at-risk patients who are starting or are candidates for steroids while awaiting the results of diagnostic tests. Even in the outpatient setting, in the presence of a risk factor for strongyloidiasis, empiric treatment (usually one dose) should be considered if it is not contraindicated and serology is not available. However, during the study period, ivermectin was only available as a foreign medication in Spain, which complicated this approach, as the results show. The recent marketing of ivermectin in Spain could facilitate compliance with this strategy. Another problem with this strategy would be the lack of screening, which would prevent real data being available on the magnitude of the problem of this infection.

Although it brings to light the situation regarding diagnosis of strongyloidiasis in Spain, the study is not without its limitations. On the one hand, the participants were not asked about the number of cases screened, which does not allow an estimation of the real prevalence. Furthermore, the survey did not elicit data on the characteristics of patients with hyperinfestation and it would have been useful to define this group's characteristics better.

In conclusion, COVID-19 has brought to light the need to harmonise screening and treatment protocols for other imported pathologies such as strongyloidiasis. As with other neglected diseases, an effort should be made to spread awareness to ensure that this potentially fatal pathology is adequately treated, particularly in patients with a higher risk of complications, such as those with COVID-19.

## Acknowledgements

The authors wish to thank Javier Ávila and the other members of the SEIMC secretariat for their technical support in carrying out the work.

## Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.eimc.2021.11.010>.

## References

1. Eslahi AV, Badri M, Nahavandi KH, Houshmand E, Dalvand S, Riahi SM, et al. Prevalence of strongyloidiasis in the general population of the world: a systematic review and meta-analysis. *Pathog Glob Health*. 2021;115:7–20.
2. Krolewiecki A, Nutman TB. Strongyloidiasis: a neglected tropical disease. *Infect Dis Clin North Am*. 2019;33:135–51.

3. Ming DK, Armstrong M, Lowe P, Chiodini PL, Doherty JF, Whitty CJM, et al. Clinical and diagnostic features of 413 patients treated for imported Strongyloidiasis at the hospital for tropical diseases, London. *Am J Trop Med Hyg.* 2019;101:428–31.
4. Salvador F, Treviño B, Chamorro-Tojeiro S, Pou D, Herrero-Martínez JM, Rodríguez-Guardado A, et al. Epidemiological and clinical profile of immunosuppressed patients with imported strongyloidiasis: a substudy from a larger cohort of the +REDIVI Spanish Collaborative Network. *Pathog Glob Health.* 2021;115:121–4.
5. Al-Obaidi M, Hasbun R, Vigil KJ, Edwards AR, Chavez V, Hall DR, et al. Seroprevalence of *Strongyloides stercoralis* and evaluation of universal screening in kidney transplant candidates: a single-center experience in Houston (2012–2017). *Open Forum Infect Dis.* 2019;6:ofz172.
6. Miglioli-Galvão L, Pestana JOM, Santoro-Lopes G, Torres Gonçalves R, Requião Moura LR, Pacheco Silva Á, et al. Severe *Strongyloides stercoralis* infection in kidney transplant recipients: a multicenter case-control study. *PLoS Negl Trop Dis.* 2020;14:e0007998.
7. Ahmadpour E, Ghanizadegan MA, Razavi A, Kangari M, Seyfi R, Shahdust M, et al. *Strongyloides stercoralis* infection in human immunodeficiency virus-infected patients and related risk factors: a systematic review and meta-analysis. *Transbound Emerg Dis.* 2019;66:2233–43.
8. Schulz J, Hyson P, Chastain DB, Gharamti AA, Franco-Paredes C, Henao-Martínez AF. Covid-19 epidemic in the US-A gateway to screen for tuberculosis, HIV, hepatitis, Chagas disease, and other neglected tropical diseases among Hispanics. *Plos Negl Trop Dis.* 2020;14:e0008953.
9. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med.* 2021;384:693–704.
10. Recovery collaborative group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet.* 2021;397:1637–45.
11. Genta RM. Dysregulation of strongyloidiasis: a new hypothesis. *Clin Microbiol Rev.* 1992;5:345–55.
12. De Wilton A, Nabarro LE, Godbole GS, Chiodini PL, Boyd A, Woods K. Risk of *Strongyloides* Hyperinfection syndrome when prescribing dexamethasone in severe COVID-19. *Travel Med Infect Dis.* 2021;40:101981.
13. Shirley DA, Moonah S. COVID-19 and corticosteroids: unfamiliar but potentially fatal infections that can arise following short-course steroid treatment. *Am J Trop Med Hyg.* 2021;104:790–3.
14. Mafort TT, Reis LVT, Faria LV, Silva RV, Miranda CS, Oliveira JP. Alveolar hemorrhage secondary to infection by *Strongyloides Stercoralis* in immunosuppressed patient - case report. *Am J Respir Crit Care Med.* 2017;195:A5586.
15. Downey C. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: a literature review. *Int J Rheum Dis.* 2016;19:536–50.
16. Boatrig MD, Wang BWE. Clinical infection with *Strongyloides stercoralis* following etanercept use for rheumatoid arthritis. *Arthritis Rheum.* 2005;52:1336–7.
17. Asundi A, Belivsky A, Liu XJ, Akaberi A, Schwarzer G, Bisoffi Z, et al. Prevalence of strongyloidiasis and schistosomiasis among migrants. *Lancet Glob Health.* 2019;7:e236–48.
18. Salvador F, Treviño B, Chamorro-Tojeiro S, Sánchez-Montalvá A, Herrero-Martínez JM, Rodríguez-Guardado A, et al. Imported strongyloidiasis: data from 1245 cases registered in the +REDIVI Spanish Collaborative Network (2009–2017). *PLoS Negl Trop Dis.* 2019;13:e0007399.
19. Geri G, Rabbat A, Mayaux J, Zafrani L, Chalumeau-Lemoine L, Guidet B, et al. *Strongyloides stercoralis* hyperinfection syndrome. *Infection.* 2015;43:691–8.
20. Guijarro C, Pérez-Fernández E, González-Piñero B, Meléndez V, Goyanes MJ, Renilla ME, et al. Differential risk for COVID-19 in the first wave of the disease among Spaniards and migrants from different areas of the world living in Spain. *Rev Clin Esp (Barc).* 2021;221:264–73.
21. Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalá J, Pachón J, et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. *Clin Microbiol Infect.* 2020;26:1525–36.
22. Boggild AK, Libman M, Greenaway C, McCarthy AE, Committee to Advise on Tropical Medicine and Travel (CATMAT). CATMAT statement on disseminated strongyloidiasis: prevention, assessment and management guidelines. *Can Comm Dis Rep.* 2016;42:12–9.
23. European Centre for Disease Prevention and Control. Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA. Stockholm: ECDC; 2018.
24. Mateos González M, Sierra Gonzalo E, Casado López I, Arnalich Fernández F, Beato Pérez JL, Monge Monge D, et al. The prognostic value of eosinophil recovery in COVID-19: a multicentre, retrospective cohort study on patients hospitalised in Spanish hospitals. *Clin Med.* 2021;10:305.
25. Requena-Méndez A, Chiodini P, Bisoffi Z, Buonfrate D, Gotuzzo E, Muñoz J. The laboratory diagnosis and follow up of strongyloidiasis: a systematic review. *PLoS Negl Trop Dis.* 2013;7:e2002.
26. Buonfrate D, Sequi M, Mejia R, Cimino RO, Krolewiecki AJ, Albonico M, et al. Accuracy of five serologic tests for the follow up of *Strongyloides stercoralis* infection. *PLoS Negl Trop Dis.* 2015;9:e0003491.
27. Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). *Clin Microbiol Infect.* 2018;24 Suppl 2:S21–40.
28. Rodríguez-Baño J, Pachón J, Carratalá J, Ryan P, Jarrín I, Yllescas M, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyper-inflammatory state: a multicentre cohort study (SAM-COVID-19). *Clin Microbiol Infect.* 2021;27:244–325.
29. Marchese V, Crosato V, Gulletta M, Castelnuovo F, Cristini G, Matteelli A, et al. *Strongyloides* infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. *Infection.* 2020;10:1–4.
30. Lier AJ, Tuan JJ, Davis MW, Paulson N, McManus D, Campbell S, et al. Case report: disseminated Strongyloidiasis in a patient with COVID-19. *Am J Trop Med Hyg.* 2020;103:1590–2.
31. Stauffer WM, Alpern JD, Walker PF. COVID-19 and dexamethasone: a potential strategy to avoid steroid-related *Strongyloides* hyperinfection. *J Am Med Assoc.* 2020;324:623–4.